Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Sofinnova closes second crossover fund at €725M for late-stage European biotechs

Sofinnova Partners has secured €725 million ($815 million) for its second crossover fund, which it said would fill the financing gap for late-stage European biopharma and medtech companies. Europe has the science and the companies ...

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

Read the original at endpoints.news →

More in Health & Medicine

More from Monday 16 November →